CliffBio
small molecule

XHANCE

FLUTICASONE PROPIONATE

Loss of exclusivityFebruary 2036latest FDA-listed patent expiry
CompanyParatek Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameXHANCE
Active ingredientFLUTICASONE PROPIONATE
Strength0.093MG/SPRAY
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalSeptember 2017
Marketing statusRX

Listed patents

PatentExpiresType
11554229February 2036use U-2133
12616806February 2036use U-4525
12083270April 2031use U-2133

Regulatory exclusivity

CodeExpires
I-940March 2027

More from Paratek Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XHANCE patent cliff — loss of exclusivity February 2036 | CliffBio